Entera Bio (ENTX) Long-Term Investments (2020 - 2026)
Entera Bio's (ENTX) quarterly Long-Term Investments came in at $6000.0 in Q1 2026, little changed YoY from $6000.0 in Q1 2025, and little changed on a QoQ basis from $6000.0 in Q4 2025.
Entera Bio (ENTX) Long-Term Investments (2020 - 2026) Analysis & Trends
Entera Bio (ENTX) has 7 years of Long-Term Investments data on file, last reported at $6000.0 in Q1 2026.
- Quarterly Long-Term Investments changed 0.0% year-over-year to $6000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $6000.0 (changed 0.0% YoY) and the FY2025 annual result came in at $6000.0, changed 0.0% from the prior year.
- Long-Term Investments was little changed at $6000.0 in Q1 2026, from $6000.0 in the prior quarter.
- In the past five years, Long-Term Investments ranged from a high of $46000.0 in Q1 2022 to a low of $6000.0 in Q3 2022.
- A 5-year average of $10705.9 and a median of $6000.0 in 2022 frame the typical range for Long-Term Investments.
- Annual changes were most pronounced in 2022 — Long-Term Investments slumped 86.96% — and 2023, when it changed 0.0%.
- Tracing ENTX's Long-Term Investments over 5 years: stood at $6000.0 in 2022, then changed by 0.0% to $6000.0 in 2023, then changed by 0.0% to $6000.0 in 2024, then changed by 0.0% to $6000.0 in 2025, then changed by 0.0% to $6000.0 in 2026.
- The last three Long-Term Investments figures came in at $6000.0 (Q1 2026), $6000.0 (Q4 2025), and $6000.0 (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Long-Term Investments (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 5.79 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 9.83 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 1.77 Bn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | - |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 22.17 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | - |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | - |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 372.10 Mn |
| 10 | Entera Bio | 161.44 Mn | 150.13 Mn | - | 6,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 6,000.00 |
| Mar 31, 2026 | 6,000.00 |
| Dec 31, 2025 | 6,000.00 |
| Sep 30, 2025 | 6,000.00 |
| Jun 30, 2025 | 6,000.00 |
| Mar 31, 2025 | 6,000.00 |
| Dec 31, 2024 | 6,000.00 |
| Sep 30, 2024 | 6,000.00 |
| Jun 30, 2024 | 6,000.00 |
| Mar 31, 2024 | 6,000.00 |
| Dec 31, 2023 | 6,000.00 |
| Sep 30, 2023 | 6,000.00 |
| Jun 30, 2023 | 6,000.00 |
| Mar 31, 2023 | 6,000.00 |
| Dec 31, 2022 | 6,000.00 |
| Sep 30, 2022 | 6,000.00 |
| Jun 30, 2022 | 46,000.00 |
| Mar 31, 2022 | 46,000.00 |
| Dec 31, 2021 | 46,000.00 |
| Dec 31, 2020 | 47,000.00 |